John W. Childs
John W. Childs's purchase track record
How the stock did after each of John W. Childs's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/5/2026 | MANE | $5.00M | +190.2% | +192.4% | +13.4% |
| 11/13/2025 | BHVN | $25.00M | +42.3% | +11.6% | +11.3% |
| 3/4/2025 | BHVN | $996K | -49.7% | -49.4% | +11.0% |
| 12/30/2024 | BHVN | $1.04M | -32.8% | -60.6% | +5.1% |
| 10/2/2024 | BHVN | $1000K | -22.3% | -50.7% | -0.7% |
| 7/18/2024 | BHVN | $1.01M | +48.8% | +3.3% | +7.1% |
| 5/30/2024 | BHVN | $996K | +13.0% | +30.6% | +15.2% |
| 5/13/2024 | BHVN | $1.00M | +9.4% | +55.2% | +14.9% |
| 4/22/2024 | BHVN | $8.00M | -4.9% | +33.9% | +16.8% |
| 10/5/2023 | BHVN | $10.00M | +75.4% | +116.7% | +20.9% |
| 8/30/2023 | BHVN | $922K | +74.3% | +156.8% | +12.3% |
| 8/4/2023 | BHVN | $1.98M | +56.5% | +127.5% | +10.7% |
| 10/25/2022 | BHVN | $40.95M | +30.0% | -6.9% | +5.5% |
| 10/5/2022 | BHVN | $2.46M | +19.6% | +5.9% | +8.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.
Transaction History
| MANE | ▼ Sell | Open Market | 5,000 | $541K | 8/12/2026 | View on chart |
| MANE | ▼ Sell | Open Market | 15,000 | $1.6M | 8/12/2026 | View on chart |
| MANE | ▼ Sell | Open Market | 80,000 | $8.6M | 8/12/2026 | View on chart |
| MANE | ▼ Sell | Other | 520,758 | — | 2/5/2026 | View on chart |
| MANE | ▲ Buy | Open Market | 294,117 | $5.0M | 2/5/2026 | View on chart |
| MANE | ▼ Sell | Other | 480,269 | — | 2/5/2026 | View on chart |
| MANE | ▼ Sell | Other | 906,862 | — | 2/5/2026 | View on chart |
| BHVN | ▲ Buy | Open Market | 3,333,333 | $25.0M | 11/13/2025 | View on chart |
| BHVN | ▲ Buy | Open Market | 25,000 | $760K | 3/4/2025 | View on chart |
| BHVN | ▲ Buy | Open Market | 3,400 | $104K | 3/4/2025 | View on chart |
| BHVN | ▲ Buy | Open Market | 3,400 | $104K | 3/4/2025 | View on chart |
| BHVN | ▲ Buy | Open Market | 900 | $28K | 3/4/2025 | View on chart |
| BHVN | ▲ Buy | Open Market | 29,000 | $1.0M | 12/30/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 21,052 | $1000K | 10/2/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 28,400 | $1.0M | 7/18/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 28,000 | $996K | 5/30/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 28,500 | $1.0M | 5/13/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 24,391 | $1.0M | 4/22/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 97,560 | $4.0M | 4/22/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 73,170 | $3.0M | 4/22/2024 | View on chart |
| BHVN | ▲ Buy | Grant | 2,091 | — | 4/5/2024 | View on chart |
| BHVN | ▲ Buy | Grant | 19,412 | — | 3/8/2024 | View on chart |
| BHVN | ▼ Sell | Other | 48,505 | — | 1/8/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 136,545 | $3.0M | 10/5/2023 | View on chart |
| BHVN | ▲ Buy | Open Market | 318,000 | $7.0M | 10/5/2023 | View on chart |
| BHVN | ▲ Buy | Open Market | 50,000 | $922K | 8/30/2023 | View on chart |
| BHVN | ▲ Buy | Open Market | 100,000 | $2.0M | 8/4/2023 | View on chart |
| BHVN | ▲ Buy | Open Market | 3,900,000 | $41.0M | 10/25/2022 | View on chart |
| BHVN | ▲ Buy | Open Market | 241,300 | $2.1M | 10/5/2022 | View on chart |
| BHVN | ▲ Buy | Open Market | 32,841 | $318K | 10/5/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 4,119 | $20K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 5,998 | $21K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 5,507 | $41K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 1,517,500 | $0 | 10/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Veradermics Momentum Builds, But H2 2026 Readouts Caution
Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.
Veradermics Momentum Builds, But H2 2026 Readouts Caution. Veradermics has seen growing momentum, but analysts caution that upcoming H2 2026 readouts could influence the stock. The company was included among 12 healthcare stocks that moved higher in Thursday’s intraday session. While the news highlights positive sentiment, investors should note the caution about future readouts. The stock remains near its 52‑week low, with a support level at $97.79.